AstraZeneca’s phase 3 trial of efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), has failed to meet its primary endpoint, casting uncertainty on the company’s ambitions to broaden its market beyond pediatric patients. The Hickory trial, which tested the therapy in adolescents and adults, showed that efzimfotase alfa did not significantly outperform placebo in improving performance on the six-minute walk test (6MWT) at Week 25. While AstraZeneca noted that the placebo group performed better than expected, the results raise questions about the viability of expanding treatment to older patients, a key strategy for increasing the total addressable market for the successor to Strensiq.

Despite this setback, AstraZeneca reported positive outcomes from the Mulberry trial, which focused on children with HPP who had not previously received Strensiq. This trial achieved its primary endpoint, demonstrating statistically significant improvements in bone health at Week 25 compared to placebo. Additionally, secondary endpoints assessing physical function and rickets severity also showed favorable results. The company is optimistic about the potential of efzimfotase alfa in pediatric populations, even as it faces challenges in the adult market.

For professionals in the longevity and healthspan research fields, the implications of these findings are significant. The contrasting outcomes between the Hickory and Mulberry trials highlight the complexities of developing therapies for rare metabolic diseases across different age groups. As AstraZeneca prepares to present its data at medical meetings and submit it for regulatory review, the ongoing evaluation of efzimfotase alfa’s safety and efficacy, particularly in pediatric patients, will be crucial for its future in the therapeutic landscape. The company’s focus on manufacturing cost advantages may also influence market dynamics and accessibility for patients.

Source: fiercebiotech.com